International generic name
Drug form and composition
Solution for injection. One ampoule of 1 ml contains 1 mg Atropine sulfate (1
Cholelithiasis and nephrolithiasis manifesting with spastic pain; ulcer disease;
pylor constriction; cholecystitis; bronchial asthma; acute intoxications with cholinergic
agents and digitalis glycosides.
Dosage and administration
Solution for injection - subcutaneous, intramuscular and intravenous application.
Dosage for adults is 0.25-1 mg, 1-3 times daily. Maximal single dose is 1 mg, whereas
the maximal dose is 3 mg per 24 hours. When Atropine is used as a counter-position
in intoxication with phosphoorganic compounds, the daily dose may be enhanced -
1 mg of the medicine is injected in intervals of 15 minutes intramuscularly or intravenously.
In children the preparation is injected subcutaneously or intravenously in dose
0.01 mg per kg body weight, each 4-6 hours, if necessary.
Glaucoma; urinary bladder and intestinal atonia; prostate gland hypertrophy;
pylor stenosis; tachyarrhythmia and heart failure; reflux-esophagitis; active pulmonary
tuberculosis. Pregnancy in the prenatal period and lactation - the preparation passes
through the placenta and is excreted in the mother milk, which may lead to intoxication
of the fetus and the infant.
Special warnings and precautions
Atropine should be used with caution in patients with renal and hepatic insufficiency;
hyperthyroidism; cardiac rhythm disorders; and coronary artery disease. During the
treatment the patient should not drive and operate machinery.
Amantadine, chinidine, three- and fourcyclet antidepressants, and neuroleptics
all potentiate the anticholinergic action of Atropine. Atropine antagonizes the
M-cholinomymetic effect of nivalin, pilocarpine, and neostigmine. In concomitant
application of Atropine and H1- blockers, disopyramide, and antiparkinsonic medicines
a sedative effect may appear.
Due to absorption and systemic action of Atropine following adverse reactions
may appear: xerostomia; mydriasis; cycloplegia, intraocular pressure elevation and
risk of glaucoma attack in patients with glaucoma; urine retention, particularly
in patients with prostate gland hypertrophy; atonic constipation; irritability and
confusion in elder patients. Mouth drying and palpitations may appear.
Atropine is an antagonist of the M-choline receptors. It abolishes the parasympathetic
influence on the target organs as well as the M-cholinomymetic action of the anticholinesterase
agents. Blocking M-cholinoreceptors, Atropine disturbs the neural impulse conduction
from postganglionergic cholinergic nerves to effector organs, including exogene
and endogene secreting glands, the heart; smooth muscles of the gastrointestinal
tract, billiary and urinary pathways. Atropine dilates the pupil and paralyses the
accommodation. Atropine is a caunter-poison in intoxication with all agents, acting
by M-choline receptor influence, as it penetrates in CNS and eliminates central
effects of toxins.
10 ampoules of 1 ml (1 mg). 100 ampoules of 1 ml (1 mg).